The first patient use was for an ankle surgery. The debut marks Ossium Health’s entrance into the orthobiologics market.
“We’ve always strived to maximize the positive impact of each organ donor’s generous gift,” Kevin Caldwell, the company’s president, CEO and co-founder, said in the release. “First, we developed a life-saving product from organ donor bone marrow, which didn’t previously have an established therapeutic application. With the development of OssiGraft, we’re expanding the impact of each donor’s gift even further.”
